financetom
Business
financetom
/
Business
/
TFG Marine to lease 4 new methanol bunker barges from Consort Bunkers
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TFG Marine to lease 4 new methanol bunker barges from Consort Bunkers
Jul 29, 2024 4:29 AM

July 29 (Reuters) - TFG Marine, a marine fuel supplier

majority owned by commodities trader Trafigura, said

on Monday it signed a long-term agreement with Consort Bunkers

to charter four new barges that can deliver various low-carbon

fuels to ships.

The shipping sector is striving to meet decarbonisation

targets by using low-carbon fuels ranging from biofuels to

methanol and ammonia to reduce emissions.

TFG Marine is one of the top three bunker fuel suppliers in

Singapore, the world's top refuelling port. It will take

delivery of the four 6,500-deadweight ton IMO type 2 tankers in

late 2024 and into 2025, it said in a statement.

These barges will form part of TFG Marine's ongoing efforts

to renew its fleet to carry low-carbon fuels that will help

shipping to decarbonise, said Kenneth Dam, TFG Marine's global

head of bunkering.

"We see a multi-fuel future for our industry, with methanol,

biofuels, ammonia, and more all playing a role alongside

traditional marine fuels in meeting the goals of the Paris

Agreement," he said.

The vessels will be capable of carrying conventional marine

fuels and biofuels up to B100, as well as any grade of liquid

methanol in the future, TFG Marine said.

These tankers will be equipped with Mass Flow Meters (MFM)

to accurately measure bunker flows for transparency, it added.

In January, TFG Marine agreed to lease a methanol dual-fuel

bunker barge being built by the Fratelli Cosulich Group to be

delivered in late 2025 for marine fuel sales at the Singapore

port.

Other partners in TFG Marine include shipowners Frontline ( FRO )

and Golden Ocean ( GOGL ).

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Mondelez Set to Be Fined by European Regulators Over Cross-Border Sales Restrictions
Market Chatter: Mondelez Set to Be Fined by European Regulators Over Cross-Border Sales Restrictions
Apr 16, 2024
08:30 AM EDT, 04/16/2024 (MT Newswires) -- Mondelez ( MDLZ ) will be fined millions of euros by the European Commission as early as May for restricting sales of its products between European Union member states, the Financial Times reported, citing unnamed sources. The maker of Oreo cookies was first asked by the EU about its alleged blocking of sales...
Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark
Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark
Apr 16, 2024
08:26 AM EDT, 04/16/2024 (MT Newswires) -- Enlivex Therapeutics ( ENLV ) said Tuesday that the Danish Medicines Agency has authorized the expansion of its phase 1/2 trial evaluating Allocetra in patients with moderate to severe knee osteoarthritis. The first stage of the trial will test the safety and tolerability of Allocetra injections to identify the dose and injection regimen...
What's Going On With Bank Of New York Mellon Shares After Reporting Q1 Results?
What's Going On With Bank Of New York Mellon Shares After Reporting Q1 Results?
Apr 16, 2024
The Bank Of New York Mellon Corporation ( BK ) shares are trading higher in the premarket session on Tuesday. The finance behemoth reported first-quarter adjusted earnings per share of $1.29, beating the street view of $1.19. Quarterly revenue of $4.527 billion outpaced the analyst consensus of $4.388 billion. “In the first quarter, we delivered double-digit EPS growth as well as pre-tax margin and...
Lexeo Says AAV-Based Gene Therapy Candidate Gets US FDA's Fast Track Designation for Friedreich's Ataxia Cardiomyopathy
Lexeo Says AAV-Based Gene Therapy Candidate Gets US FDA's Fast Track Designation for Friedreich's Ataxia Cardiomyopathy
Apr 16, 2024
08:26 AM EDT, 04/16/2024 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Tuesday that its AAVrh.10hFXN-based gene therapy candidate has received fast-track designation from the US Food and Drug Administration to treat Friedreich's ataxia cardiomyopathy. The candidate, LX2006, is developed to provide a functional frataxin gene for promoting frataxin protein expression and restoring mitochondrial function in myocardial cells, the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved